On April 5, 2022, Andrew Einhorn resigned as the Chief Financial Officer of RVL Pharmaceuticals plc (the “Company”), effective April 18, 2022. Mr. Einhorn currently serves as the Company's principal financial officer and principal accounting officer. Mr. Einhorn's decision did not result from a disagreement with the Company on any matter relating to the Company's operations, policies or practices.

Upon the effectiveness of Mr. Einhorn's resignation, Brian Markison, Chief Executive Officer of the Company, will serve as the principal financial officer of the Company and Michael J. DePetris, who the Company engaged in January 2022 as a senior financial advisor and who, among other duties, assisted in preparing the Company's Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission on March 30, 2022 (the “Annual Report”), will serve as the principal accounting officer of the Company.